These results exemplify how PLA repeat testing of lesions that may have evolved over time after the initial negative PLA test, can identify early-stage melanoma and benefit patients. “These results ...
LA JOLLA, Calif.--(BUSINESS WIRE)-- DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results